NCT01689038

Brief Summary

Assess the binding rate of F17464 to cerebral receptors in healthy volunteers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for phase_1 healthy-volunteers

Timeline
Completed

Started Nov 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 14, 2012

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 20, 2012

Completed
1 month until next milestone

Study Start

First participant enrolled

November 1, 2012

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2013

Completed
Last Updated

February 15, 2013

Status Verified

February 1, 2013

Enrollment Period

3 months

First QC Date

September 14, 2012

Last Update Submit

February 13, 2013

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (1)

  • Binding rate to cerebral receptors

    by brain imaging

    up to 29 hours

Study Arms (1)

Tested product

EXPERIMENTAL
Drug: F17464

Interventions

F17464DRUG

Single dose

Tested product

Eligibility Criteria

Age18 Years - 55 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Male healthy volunteers

You may not qualify if:

  • Presence or positive history of severe medical illness or psychiatric conditions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unknown Facility

New York, New York, United States

Location

MeSH Terms

Interventions

dopamine D3 receptor antagonist F17464

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 14, 2012

First Posted

September 20, 2012

Study Start

November 1, 2012

Primary Completion

February 1, 2013

Study Completion

February 1, 2013

Last Updated

February 15, 2013

Record last verified: 2013-02

Locations

US(1)